{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T20:17:52Z","timestamp":1761164272126,"version":"build-2065373602"},"reference-count":73,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":3913,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2001,5]]},"abstract":"<jats:p>Inflammation plays a primary role in the pathogenesis of cystic fibrosis (CF)\u2010related lung disease. Controlling the inflammatory process with antiinflammatory therapy may slow the progression of pulmonary disease and thereby decrease morbidity. Despite potential benefits of antiinflammatory therapy, both the decision to treat and selection of the most appropriate therapeutic agent are controversial. Although oral corticosteroids are associated with reduced progression of pulmonary disease, the risk of clinically significant adverse effects limits long\u2010term therapy. Clinical studies with inhaled corticosteroids failed to report positive effects on reducing airway inflammation. Based on available clinical data, routine therapy with these agents should be limited to patients with asthma or steroid\u2010responsive wheezing. High\u2010dosage ibuprofen has a beneficial effect on reducing the annual rate of decline in pulmonary function in patients with mild lung disease. Whereas initial results are encouraging, they do not support routine ibuprofen therapy in all patients with CF. However, as advocated by the Cystic Fibrosis Foundation, high\u2010dosage ibuprofen may be considered in children 5\u201312 years of age with a baseline forced expiratory volume of 60% predicted or greater.<\/jats:p>","DOI":"10.1592\/phco.21.6.593.34546","type":"journal-article","created":{"date-parts":[[2004,6,9]],"date-time":"2004-06-09T06:25:36Z","timestamp":1086762336000},"page":"593-603","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Inflammation and Cystic Fibrosis Pulmonary Disease"],"prefix":"10.1002","volume":"21","author":[{"given":"Mary Jayne","family":"Kennedy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)83478-X"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.154.5.8912731"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-0496(199708)24:2<137::AID-PPUL13>3.0.CO;2-3"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.152.6.8520783"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70116-8"},{"issue":"27","key":"e_1_2_1_7_2","first-page":"8","article-title":"Role of corticosteroids in cystic fibrosis lung disease","volume":"89","author":"Balfour\u2010Lynn I.M.","year":"1996","journal-title":"J R Soc Med"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.150.1.7912987"},{"key":"e_1_2_1_9_2","first-page":"1075","article-title":"Early pulmonary inflammation in infants with cystic fibrosis","volume":"151","author":"Khan T.Z.","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.1950200203"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.4.96-11058"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.150.2.8049828"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.310.6994.1571"},{"key":"e_1_2_1_14_2","first-page":"115","volume-title":"Cystic fibrosis in adults","author":"Berger M.","year":"1999"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/175.3.638"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.1.9808096"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.105.1.32"},{"key":"e_1_2_1_18_2","first-page":"S59","article-title":"Effects of glucocorticoids on inflammatory cells relevant to their therapeutic applications in asthma","volume":"141","author":"Schleimer R.P.","year":"1990","journal-title":"Am Rev Respir Dis"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb\/9.4.455"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)92929-0"},{"key":"e_1_2_1_21_2","first-page":"277","article-title":"Long\u2010term alternate day prednisone therapy in cystic fibrosis [abstr]","volume":"5","author":"Donati M.A.","year":"1990","journal-title":"Pediatr Pulmonol"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(95)70343-8"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1542\/peds.87.2.245","article-title":"Risks of alternate\u2010day prednisone in patients with cystic fibrosis","volume":"87","author":"Rosenstein B.J.","year":"1991","journal-title":"Pediatrics"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.115.4.1053"},{"key":"e_1_2_1_25_2","first-page":"383","volume-title":"Cystic fibrosis in adults","author":"Robbins M.K.","year":"1999"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0954-6111(95)90249-X"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(96)70407-9"},{"key":"e_1_2_1_28_2","first-page":"A72","article-title":"A double\u2010blind, placebo\u2010controlled study comparing the effects of the inhaled corticosteroid fluticasone propionate 500 \u03bcg BID with placebo in adults with cystic fibrosis [abstr]","volume":"153","author":"Neiman R.","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.4.9612044"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.77.2.124"},{"key":"e_1_2_1_31_2","first-page":"105","article-title":"Inhaled corticosteroid treatment in infants and young children with cystic fibrosis","volume":"19","author":"Wojtczak H.A.","year":"1999","journal-title":"Pediatr Pulmonol Suppl"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.97.10071640"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)03339-9"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.48.6.599"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.9.941"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.151.6.7767512"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.150.3.8087329"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(98)70260-X"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(98)70156-3"},{"key":"e_1_2_1_40_2","first-page":"293","article-title":"Is the acquisition of pseudomonads in cystic fibrosis patients increased by use of inhaled corticosteroids? Unexpected results from a double\u2010blind placebo controlled study","volume":"14","author":"Schmidt J.","year":"1997","journal-title":"Pediatr Pulmonol Suppl"},{"volume-title":"Expert panel report 2: guidelines for the diagnosis and management of asthma","year":"1997","author":"National Asthma Education and Prevention Program.","key":"e_1_2_1_41_2"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600731020"},{"key":"e_1_2_1_43_2","first-page":"152","article-title":"Effect of ibuprofen on neutrophil (PMN) delivery to mucosal surfaces","volume":"4","author":"Konstan M.W.","year":"1989","journal-title":"Pediatr Pulmonol Suppl"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/141.1.186"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/148.4_Pt_1.896"},{"key":"e_1_2_1_46_2","first-page":"274","article-title":"Leukotriene B4 production by neutrophils from subjects receiving high dose ibuprofen [abstr]","volume":"17","author":"Walenga R.W.","year":"1998","journal-title":"Pediatr Pulmonol Suppl"},{"volume-title":"Questions and answers\u2014ibuprofen: information for cystic fibrosis physicians","year":"1995","author":"Cystic Fibrosis Foundation.","key":"e_1_2_1_47_2"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199503303321303"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)82218-8"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199204303261804"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1978.tb16273.x"},{"key":"e_1_2_1_52_2","first-page":"236","volume-title":"Perspectives in cystic fibrosis: proceedings of the eighth International Cystic Fibrosis Congress, Toronto, May 26\u201330, 1980","author":"Wagener J.S.","year":"1980"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-5231(05)70096-4"},{"volume-title":"1998 annual data report. Patient registry","year":"1999","author":"Cystic Fibrosis Foundation.","key":"e_1_2_1_54_2"},{"key":"e_1_2_1_55_2","first-page":"322","article-title":"Clinical use of ibuprofen for cystic fibrosis lung disease: data from the 1996 CFF patient registry [abstr]","volume":"14","author":"Konstan M.W.","year":"1997","journal-title":"Pediatr Pulmonol Suppl"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199801013380115"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199306173282403"},{"key":"e_1_2_1_58_2","unstructured":"Cystic Fibrosis Ibuprofen Laboratory.Available fromhttp:www.cwru.eduaffilCFIBUPLABphysgen.htm. AccessedJuly 25 2000."},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(99)70387-2"},{"volume-title":"Clinical outcomes consensus conference report","year":"1992","author":"Cystic Fibrosis Foundation.","key":"e_1_2_1_60_2"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.156.5.9701098"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.2000.15e24.x"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91167-S"},{"key":"e_1_2_1_64_2","first-page":"421","article-title":"Aerosolized Prolastin (\u03b11\u2010protease inhibitor) in CF [abstr]","volume":"20","author":"Berger M.","year":"1995","journal-title":"Pediatr Pulmonol Suppl"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115994"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.110.6_Supplement.261S"},{"key":"e_1_2_1_67_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/148.4_Pt_1.1056"},{"issue":"17","key":"e_1_2_1_68_2","first-page":"136","article-title":"DMP777: a synthetic human neutrophil\u2010elastase inhibitor as therapy for cystic fibrosis","volume":"26","author":"Vender R.L.","year":"1998","journal-title":"Pediatr Pulmonol"},{"issue":"37","key":"e_1_2_1_69_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/014107689909237S05","article-title":"The protease\u2010antiprotease battle in the cystic fibrosis lung","volume":"92","author":"Balfour\u2010Lynn I.M.","year":"1999","journal-title":"J R Soc Med"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.6.9901043"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)78360-4"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.66.3.401"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.3.847.bloodjournal873847"},{"key":"e_1_2_1_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3536(11)80012-0"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.21.6.593.34546","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.21.6.593.34546","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:01:44Z","timestamp":1761069704000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.21.6.593.34546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,5]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,5]]}},"alternative-id":["10.1592\/phco.21.6.593.34546"],"URL":"https:\/\/doi.org\/10.1592\/phco.21.6.593.34546","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2001,5]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}